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OBJECTIVE
To evaluate feasibility, safety, and efﬁcacy of overnight closed-loop insulin de-
livery in free-living youth with type 1 diabetes.
RESEARCH DESIGN AND METHODS
Overnight closed loop was evaluated at home by 16 pump-treated adolescents
with type 1 diabetes aged 12–18 years. Over a 3-week period, overnight insulin
delivery was directed by a closed-loop system, and on another 3-week period
sensor-augmented therapy was applied. The order of interventions was random.
The primary end point was time when adjusted sensor glucose was between 3.9
and 8.0 mmol/L from 2300 to 0700 h.
RESULTS
Closed loop was constantly applied over at least 4 h on 269 nights (80%); sensor
data were collected over at least 4 h on 282 control nights (84%). Closed loop
increased time spent with glucose in target by a median 15% (interquartile range
29 to 43; P < 0.001). Mean overnight glucose was reduced by a mean 14 (SD 58)
mg/dL (P < 0.001). Time when glucose was <70mg/dL was low in both groups, but
nights with glucose <63mg/dL for at least 20min were less frequent during closed
loop (10 vs. 17%; P = 0.01). Despite lower total daily insulin doses by a median 2.3
(interquartile range 24.7 to 9.3) units (P = 0.009), overall 24-h glucose was re-
duced by a mean 9 (SD 41) mg/dL (P = 0.006) during closed loop.
CONCLUSIONS
Unsupervised home use of overnight closed loop in adolescents with type 1 di-
abetes is safe and feasible. Glucose control was improved during the day and night
with fewer episodes of nocturnal hypoglycemia.
Achievement of tight glycemic control in type 1 diabetes is limited by hypoglycemia
(1), particularly overnight when the sympathoadrenal response to falling blood
glucose concentration is blunted, reducing warning symptoms and arousal from
sleep (2). The risk of severe hypoglycemia is the most feared adverse event among
young people with type 1 diabetes and their families, contributing to four in ﬁve
youth aged 13–18 years failing to meet the International Society for Pediatric and
Adolescent Diabetes glycemic control target of HbA1c ,7.5% (58.5 mmol/mol) (3).
Technology-assisted therapeutic approaches such as insulin pump therapy have
led to improved glycemic control and reduced risk of severe hypoglycemia (4).
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Continuous glucose monitoring enables
users to view real-time glucose readings
with alarms for impending hypo- or hy-
perglycemia facilitating appropriate
changes in insulin delivery (5). When
sensor wear is regular, continuous glu-
cose monitoring can improve glucose
control, but poor compliance is partic-
ularly prevalent in adolescents (6).
Sensor-augmented insulin pump ther-
apy combining continuous glucose mon-
itoring with insulin pump delivery
further improves glycemic control but
does not reduce risk of hypoglycemia
(7) unless combined with threshold-
based insulin pump interruptions (8,9).
Closed-loop systems differ from con-
ventional and threshold-suspend sen-
sor-augmented pump therapy through
the use of a control algorithm which au-
tomatically reduces and increases sub-
cutaneous insulin delivery according
to sensor glucose levels. Preliminary
short-duration studies (up to 2 days in
carefully controlled hospital settings)
suggest the potential to safely improve
glucose control with the model predic-
tive control algorithm in youth (10,11),
adults (12–14), and pregnant women (15)
and with proportional-integral-derivative
(16,17), fuzzy logic (18), and glucagon
coadministration approaches (19). Out-
side hospital settings, two single-night
transitional studies have been conducted,
involving a diabetes camp and hotel set-
ting, both with intensive on-site and/or
telemonitoring supervision (20,21). An in-
terim analysis of a 4-night home overnight
closed-loop study using telemonitoring
has been reported (22).
There has been no previous prolonged
evaluation of closed loop under free-
living conditions. We hypothesized that
unsupervised home use of overnight
closed loop was safe and feasible and
would improve glucose control compared
with sensor-augmented pump therapy in
young people with type 1 diabetes.
RESEARCH DESIGN AND METHODS
We carried out an open-label, random-
ized, crossover study to compare sensor-
augmented pump therapy with and
without overnight closed-loop insulin
delivery in adolescents with type 1 di-
abetes. The study was performed in
real-life conditions, with unrestricted
diet and normal school and sporting
activities and without telemonitoring or
continuous supervision. Participants aged
$16 years and parents or guardians of
participants aged #16 years signed
informed consent; written assent was ob-
tained from minors. The study was ap-
proved by the Local Research Ethics
Committee.
Setting and Subjects
The study was conducted at home with
participants recruited from Pediatric Dia-
betes Clinics at Addenbrooke’s Hospital,
Cambridge, U.K., and University College
Hospital, London, U.K., from July 2012
to March 2013. Inclusion criteria were
type 1 diabetes, age 12–18 years, .1
year from diagnosis or conﬁrmed C-
peptide–negative, insulin pump ther-
apy for at least 3 months, four or more
ﬁngerstick glucose measurements per
day, and HbA1c #10% (86 mmol/mol).
Exclusion criteria included established
nephropathy, neuropathy, or prolifera-
tive retinopathy, total daily insulin dose
$2.0 U/kg, regular use of continuous
glucose monitoring within 1 month
prior to enrollment, severe visual or
hearing impairment, pregnancy, or
breastfeeding.
Study Design
In an open-label, randomized, two-
period crossover study design, partici-
pants underwent two 21-day periods
of sensor-augmented pump therapy
with and without overnight closed loop
(Fig. 1). During both 21-day periods, par-
ticipants used the study pump and real-
time continuous glucose-monitoring
devices, the latter calibrated according
to the manufacturer’s instructions. Stan-
dard hypoglycemia and hyperglycemia
treatment guidelines were followed. The
sensor glucose alarm threshold was set at
63 mg/dL. Rapid-acting insulin analog As-
part (Novo Nordisk, Bagsvaerd, Denmark)
was used.
During one 21-day period, randomly
assigned, overnight insulin delivery was
directed by a closed-loop algorithm.
During the 2- to 3-week washout, par-
ticipants used their standard pump and
discontinued continuous glucose moni-
toring. Randomization assignment was
unblinded, but allocation between
treatment sequences was concealed to
the study staff until after randomiza-
tion, which occurred the day prior to
the ﬁrst intervention. Randomization
used permuted block-four approach.
Training and Supervision
After enrollment, participants were
trained on the speciﬁc features of the
study insulin pump (Dana R Diabecare;
Sooil, Seoul, South Korea) and continu-
ous glucose-monitoring (FreeStyle Nav-
igator; Abbott Diabetes Care, Alameda,
CA) devices (23). Over a 2–4-week run-in
phase, participants used the study pump
and continuous glucose monitor and
were required to collect at least 8 days
of sensor glucose readings to pass the
run-in phase assessment. The Navigator
receiver was modiﬁed during the run-in
phase to record sensor glucose levels but
not to display them. Data were used to
optimize insulin pump therapy.
On the ﬁrst evening of closed loop,
training was provided in the participants’
homes on operation, including initiation
and discontinuation of the closed-loop
system. Participants were instructed to
start closed loop in the evening and to
stop before breakfast. One or two mem-
bers of the study team were accommo-
dated close to participants’ homes during
the ﬁrst closed-loop night to alleviate
potential safety concerns and to super-
vise closed-loop stopping the next
morning. No further supervision took
place over the following 20 nights, and
telemonitoring was not used.
Figure 1—Design of the study evaluating overnight closed-loop delivery.
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Closed-Loop System
The Florence closed-loop system (24)
comprises a model predictive control al-
gorithm residing on a small laptop,
which is linked by cable to the sensor
receiver and controls the study pump
via wireless communication.
Every 12min, the treat-to-target algo-
rithm calculated a new insulin infusion
rate, which is automatically set on the
study pump (Supplementary Fig. 2). The
calculations use a compartment model
of glucose kinetics (25) describing the
effect of rapid-acting insulin and the car-
bohydrate content of meals on glucose
levels. Carbohydrate content was down-
loaded automatically from the study
pump. Insulin delivery history was also
downloaded including manually in-
structed insulin boluses. The algorithm
was initialized using preprogrammed
basal insulin delivery downloaded
from the study pump. Additionally, the
participant’s weight and total daily in-
sulin dose were entered at setup. Algo-
rithm version 0.3.24 with interface
version 1.0.7 was used (University of
Cambridge).
Safety Precautions During Closed
Loop
Participants performed a calibration
check before their evening meal. If sen-
sor glucose was above ﬁngerstick glu-
cose by .54 mg/dL, the continuous
glucose monitor was recalibrated, and
calibration check was repeated before
starting closed loop. These instructions
mitigated risk of sensor error and were
tested in silico (26) using the validated
Cambridge simulator (27).
If sensor glucose reading outputs be-
came unavailable or in case of other fail-
ures, the subject’s usual insulin delivery
rate automatically restarted within 30–
60 min. These measures limited the risk
of insulin under- and overdelivery (26).
The algorithm included rules that lim-
ited maximum insulin infusion and sus-
pended insulin delivery if glucose was
#77 mg/dL or when glucose was rapidly
decreasing.
Assays
Baseline randomC-peptidewasmeasured
by an immunometric assay (Siemens
Healthcare Diagnostics, Frimley, U.K.).
Sample Size
Based on 24–36 h in-patient pilot
(10,12,28), we anticipated that overnight
closed-loop insulin delivery could increase
the percentage nighttime glucose was be-
tween 70 and 144 mg/dL by a mean 24%
(SD 29%). We calculated that 16 partici-
pantswould provide80%power at the5%
level of signiﬁcance to detect such
difference between sensor-augmented
pump therapy and overnight closed-loop
insulin delivery.
Statistical Analysis
The analysis plan was agreed in ad-
vance. The primary outcome was the
time when glucose was in the target
range (70–144 mg/dL) between 2300
and 0700 h. Secondary outcomes in-
cluded mean glucose, time when glu-
cose was ,70 mg/dL (hypoglycemia),
number of nights when glucose was
,63 mg/dL for $20 min, time when
glucose was .144 mg/dL (hyperglyce-
mia), and insulin delivery. We es-
timated glycemic variability by the
coefﬁcient of variation of glucose dur-
ing nights and between nights. Previ-
ously, we showed that Navigator
sensor glucose is acceptable to esti-
mate glucose mean and variability but
may overestimate beneﬁt of closed
loop (29). We corrected for this bias
resulting from simultaneous use of
sensor glucose to both direct insulin
delivery and assess outcomes by
using a conservative stochastic trans-
formation of threshold metrics assess-
ing time glucose was in, below, and
above target (29). Stochastic transfor-
mation has been shown to provide an
unbiased estimate of time when glu-
cose is in target and below target, mak-
ing it suitable for assessment of closed
loop in outpatient settings.
We included in the primary and sec-
ondary analyses evaluable nights com-
prising at least 4 h of sensor data
(control group) or 4 h of uninterrupted
closed loop (intervention group). Each
night was analyzed to the treatment
group assigned. Secondary outcomes
were calculated for the night (2300 to
0700 h) and 24-h (frommidnight to mid-
night) period. The 24-h analysis used
days with evaluable nights and at least
12 h of sensor glucose.
For continuous outcomes, a repeated-
measures regression model with an
autoregressive ﬁrst-order covariance
structure adjusted for the period effect,
adjusted for glucose at 2100 h for night
analyses, and based on the ranked
normal transformation (except for
mean glucose, which was not trans-
formed because it already had an
approximate normal distribution) was
ﬁt to compare the two treatments.
Repeated-measures logistic regression
using generalized estimating equations
to account for the correlation from
the same subject was applied to binary
outcomes. Calculations were made us-
ing GStat software, version 2.0 (Univer-
sity of Cambridge). Statistical analyses
were conducted with the use of SAS
software, version 9.3 (SAS Institute,
Cary, NC) and SPSS, version 19 (IBM
Software, Hampshire, U.K.). Values are
reported as mean (SD) or median (inter-
quartile range) unless stated otherwise.
All P values are two-tailed, and values
,0.05 were considered statistically
signiﬁcant.
RESULTS
We approached 33 and enrolled 17
subjects to attain 16 completed partic-
ipants. The main reasons for nonpartic-
ipation were scheduling logistics (school
examinations, family vacations, etc).
One enrolled participant did not com-
plete initial training, withdrew consent,
and was excluded. Supplementary Fig. 1
shows the ﬂow of participants through
the study. Participants included 10males
and 6 females, age 15.6 (2.1) years
[mean (SD)]; diabetes duration 7.2 (4.3)
years; HbA1c 8.0 (0.9)% [63.9 (9.3)mmol/
mol]; BMI 22.4 (3.7) kg/m2; BMI z-score
0.8 (0.8); insulin pump therapy dura-
tion of 3.0 (2.3) years; total daily insulin
dose 0.8 (0.2) units/kg; and C-peptide–
negative (,33 pmol/L), except for three
participants with measurable random
nonhypoglycemia C-peptide levels of
59, 73, and 394 pmol/L.
Overnight closed loop was used on
311 nights (93%), turned on at 2134 h
(2037–2235) and turned off at 0737 h
(0701–0909), operating over 10.0 (8.7–
11.6) h. On 231 of 311 nights, closed
loop did not have any interruption (Sup-
plementary Table 1). Apart from re-
placement of faulty study devices, the
participants were able to resolve most
issues on their own, such as restarting
closed loopafter loss of pumpconnectivity
or sensor data unavailability.
Primary Outcome
Time when adjusted overnight glucose
was in the target increased during
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closed-loop therapy compared with
control nights by a median 15% (29 to
43) from 47% (18–70) to 64% (45–79)
(control nights vs. closed-loop nights;
P , 0.001). This was corroborated by
an increase in unadjusted (raw) over-
night sensor glucose by a median 19%
(212 to 50) from 46% (13–77) to 68%
(43–86) (P , 0.001) (Supplementary
Table 2).
Secondary Efﬁcacy Outcomes
Overnight
Closed loop reduced overnight glucose
by a mean 14 (SD 58) mg/dL, and time
above target range was also reduced
(both P , 0.001) (Table 1 and Fig. 2).
Glucose variability within each night in-
creased by 3% (27 to 12) (P , 0.01);
between-night glucose variability de-
creased (P, 0.003) withmore consistent
mean overnight glucose levels (Fig. 3).
This was accompanied by consistent
morning (0700 h) glucose of 121 (32)
mg/dL.
Assessments by unadjusted sensor
glucose levels supported the primary
end point ﬁndings and suggested
greater magnitude and wider beneﬁts
of closed loop, including reduced time
in hypoglycemia and hyperglycemia
(Supplementary Table 3). A subanalysis
from 0200 to 0700 h demonstrated
a more pronounced effect of closed
loop after several hours of closed-loop
operation (Supplementary Table 6).
Safety and Adverse Events
Time spent in hypoglycemia,70 mg/dL
was low in both periods. The number of
nights when glucose was,63 mg/dL for
at least 20 min was lower during closed
loop (10 vs. 17% of nights; P = 0.01).
Fingerstick glucose ,63 mg/dL further
corroborated the reduction in nocturnal
hypoglycemia. In total, ﬁngerstick glu-
cose ,63 mg/dL was measured on 8
nights during closed loop and 17 control
nights.
No serious adverse events were
observed during either study period.
Two participants measured blood ke-
tones.1.5 mmol/L one participant on
one occasion during closed loop and
one participant on two occasions dur-
ing control nights (Supplementary
Table 4). These events were attributed
to detached infusion sets or incor-
rect pump priming and were all self-
managed.
Secondary Efﬁcacy Outcomes From
Midnight to Midnight
Of days included in the night analysis,
12 h of continuous monitoring data
were available on 252 (75%) and 264
(79%) study days during closed-loop
and control therapy, respectively. Ap-
plication of overnight closed loop re-
sulted in lower glucose levels until
1100, 3.5 h after stopping closed loop
(Supplementary Fig. 3). Twenty-four–
hour glucose was reduced by a mean 9
(SD 41) mg/dL (P = 0.006) during closed-
loop therapy.
Insulin Requirements
Lower nocturnal glucose levels during
closed loop were achieved through in-
creased insulin delivery of 0.9 (20.5 to
2.8) units in the night period [8.1 (6.5–
10.8) vs. 7.2 (5.8–9.1) units; P, 0.001].
However, during the day, 3.2 (210.2 to
3.4) units less insulin was administered as
boluses [25.3 (19.8–33) vs. 28.7 (22–36.4)
units; P , 0.001], and the total daily
insulin dose decreased by 2.3 (24.7 to
9.3) units [49.9 (39.6–61.9) vs. 53.2
(42.5–61.7) units; P = 0.009].
Weekly Trends
The number of evaluable nights was
similar in each of the 3 weeks (88–91
nights). No weekly trends in glucose con-
trol or insulin delivery were observed
(Supplementary Table 5).
CONCLUSIONS
We have demonstrated the feasibility of
extended use of unsupervised overnight
closed loop in the home setting. Closed
loop increased time spent when glucose
was in the target range by a median 15%
and reduced both 24-h and overnight glu-
cose levels by a mean 14 and 9 mg/dL,
respectively. The number of nights when
glucose was ,63 mg/dL for at least 20
min was almost halved. Additional bene-
ﬁts included reduced total daily insulin
requirements.
After brief operational training (30–
60 min), closed-loop technology was
simple to initiate, with near-optimal
short-term compliance (93% nights)
documenting user-friendly interface
and simplicity of setup previously as-
sessed during user group sessions.
Closed loop was started irrespective
of evening glucose levels after
performing a safety calibration check.
Closed loop increased slightly within-
night glucose variability, explained
by a drop from evening hyperglycemia
to morning euglycemia, whereas sus-
tained elevated glucose was frequent
during control nights. Preplanned in-
person contacts took place at the start
and end of each study period to provide/
collect study devices and consumables,
take blood samples, and complete ques-
tionnaires. Subjects were in weekly tele-
phone/e-mail contact during both study
periods. Ad hoc contacts/visits took place
to resolve device issues (median 2, range
1–3 in-person visits per participant),
mostly occurring during closed-loop
intervention.
Closed loop revealed substantial,
night-to-night variability in insulin re-
quirements. The amount of insulin de-
livered by closed loop on individual
nights varied between 50 and 200% of
the amount given during control nights.
During closed loop, the median night-
to-night difference in insulin delivery
was 27%, with 1 in 10 differences
.72%. This explains difﬁculties in
achieving consistent nocturnal glucose
levels with conventional and sensor-
augmented pump therapy, providing a
compelling rationale for the closed-loop
approach. The increased variability in
insulin delivery during closed loop is off-
set by reduced variability of glucose
concentration, the typical trading of
variability associated with closed-loop
systems (Fig. 2). The lack of weekly
trends conﬁrms both that the beneﬁts
of closed loop occurred rapidly and that
they can be consistently sustained over
multiple nights.
Two short-duration transitional stud-
ies assessed the feasibility of a single
night of closed loop outside hospital, in-
corporating real-time telemonitoring
and on-site supervision by clinical re-
search staff (20,21). Another home
study evaluated overnight closed loop
over 4 consecutive nights (22). Pro-
longed on-site supervision may not be
feasible for home studies, and while
technological advances may increas-
ingly facilitate remote telemonitoring
approaches, it limits implementation in
real-life clinical settings. The only ad-
verse events observed in our study
were three instances of elevated ke-
tones, most likely related to unfamiliar-
ity with the study pump and infusion set
failures. They were all successfully self-
managed, suggesting that additional
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intensive supervision is not required for
safe application of closed loop.
The amount of nocturnal hypoglyce-
mia was less than half that compared
with the Juvenile Diabetes Research
Foundation Continuous Glucose Moni-
toring Trial in youth (30). Despite low
baseline levels, the number of nights
when sensor glucose was ,63 mg/dL
for $20 min was reduced. Phillip et al.
(20) also showed that closed loop re-
duced the number of nights with noc-
turnal hypoglycemia within a diabetes
camp setting, but with higher baseline
prevalence and higher mean glucose
compared with our results. Nimri et al.
(22) in an interim analysis showed
reduction of hypoglycemia duration
during 4-night home use of closed
loop without change in mean glucose.
To avoid overestimating the poten-
tial impact of closed loop, we per-
formed all statistical analyses using
both raw and adjusted sensor data
conﬁrming a 19 and 15% increased
time in target, respectively. Potential
limitations include a small number of
participants, which may limit generaliz-
ability, and a relatively short duration.
However, participants’ characteristics
are comparable to the U.S. T1D Ex-
change Registry (3) and U.K. national
audit (31), demonstrating that we
studied a representative population of
youth with type 1 diabetes. The
strength of the adolescents’ overnight
closed-loop study is the integration of
closed loop into a normal living routine
including school/weekdays, weekends,
holidays, and with varied diet and
sleeping patterns. Without supervision,
adolescents with type 1 diabetes
started and stopped closed loop by
their own volition over multiple nights
and without real-time monitoring or re-
dundant sensor, which will accelerate
cost-effective transition into routine
clinical care.
In conclusion, overnight closed loop
was safe, and its beneﬁts included in-
creased time when glucose is in target,
Figure 2—Sensor glucose (top panel) and insulin delivery (bottom panel) from 2300 to 0700 h. Median overnight proﬁles are represented by red
solid (closed loop) and black dashed (control therapy) lines. The interquartile range is shown as red (closed loop) and gray (control therapy) regions.
The plots demonstrate progressively tighter overnight glucose levels during closed-loop therapy brought about by more varying insulin delivery, the
typical tradeoff of insulin delivery variability for glucose consistency. The target glucose range 70–144 mg/dL is denoted by short dashed lines in the
top panel.
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reducedmean glucose, and fewer nights
with hypoglycemia. Further longer-term
studies are warranted.
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Supplementary Table 1. Failure analysis during closed loop.  
 
Number of nights when closed-loop turned on 311 
Number of nights with  
 0 events 231 (74%)
 1 event 70 (23%) 
 2 events 8 (3%) 
 3 events 0 
 4 events 1 (<1%) 
 5 events 1 (<1%) 
Total duration of closed-loop operation (h) 3053 
Number of eventsa  
             All reasons 95 
 due to battery drained 4 
 due to Companion failure  1 
 due to basal profile changed  1 
 due to extended bolus changed by user 10 
 due to temporary infusion changed by user 4 
 due to sensor data unavailability  29 
 due to lack of pump connectivity  36 
 due to other reasonsb 10 
a Event defined as undesirable stopping of closed-loop 
b Other reasons include control algorithm device failure and unknown reasons 
 
Supplementary Table 2. Primary outcome using adjusted sensor glucose values corroborated 
by unadjusted sensor glucose levels. Time when glucose in target between 23:00 and 07:00 
during overnight closed loop insulin delivery (269 evaluable nights) and sensor-augmented 
insulin pump therapy (282 evaluable nights) is reported. Values are medians (interquartile 
ranges).  
 
 Time (%) when overnight glucose in target 
rangea   
 
Closed loop 
(N=16 subjects) 
Control  
(N=16 subjects) 
Paired differenced 
(%) 
 P 
Adjusted sensor  
glucoseb 64 (45 to 79) 47 (18 to 70) +15 (−9 to +43) <0.001 
Unadjusted sensor 
glucosec 68 (43 to 86) 46 (13 to 77) +19 (−12 to +50) <0.001 
a Target range 70 to 144mg/dl. 
b Primary outcome: percentage calculated using adjusted sensor values. 
c Secondary outcome corroboration: percentage using unadjusted glucose levels  
d Closed loop minus insulin pump. Positive value indicates measurement was higher on nights 
of closed loop delivery compared with nights of pump therapy. 
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Supplementary Table 3. Outcomes using native CGM values. 
 
 
 
 
Overnight 
closed loop 
(N = 16 
subjects) 
Control  
(N = 16 
subjects) 
Paired 
differencea 
 
P 
From 23:00 to 07:00     
      Number of evaluable nights 269 282  − 
      Time spent at glucose level 
(%)b:     
           70 to 144mg/dl 68 (43 to 86) 46 (13 to 77) +19 (−12 to +50) <0.001 
           70 to 180 mg/dl 89 (68 to 100) 73 (37 to 95) +11 (−7 to +46) <0.001 
           < 54mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.05 
           < 63mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.02 
           < 70mg/dl 0.0 (0.0 to 0.2) 0.0 (0.0 to 6.2) 0.0 (−2.7 to 0.0) <0.001 
           > 144mg/dl 28.3 (11.0 to 51.8) 
43.2 (11.4 to 
86.7) 
−13.2 (−49.7 to 
+15.9) <0.001 
           > 180mg/dl 6.2 (0.0 to 27.9) 13.3 (0.0 to 58.8) 
−0.6 (−42.2 to 
+7.9) <0.001 
           > 300mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.87 
From midnight to midnight (24 
hours) 
    
 
     Number of evaluable days 252 264  − 
     Time spent at glucose level 
(%)b:     
          70 to 144mg/dl 51 (37 to 64) 40 (23 to 56) +11 (−7 to +28) <0.001 
          70 to 180 mg/dl 70 (56 to 83) 61 (44 to 76) +8 (−7 to +25) <0.001 
          < 54mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 1.3) 0.0 (−0.2 to 0.0) 0.05 
          < 63mg/dl 0.0 (0.0 to 1.9) 0.0 (0.0 to 4.0) 0.0 (−1.9 to +0.8) 0.11 
          < 70mg/dl 1.3 (0.0 to 4.0) 1.7 (0.0 to 8.1) 0.0 (−4.2 to +2.1) 0.10 
          > 144mg/dl 45.7 (31.6 to 60.3) 
53.5 (35.7 to 
75.6) 
−9.2 (−28.2 to 
+9.9) <0.001 
          > 180mg/dl 25.1 (12.9 to 41.7) 
33.0 (17.0 to 
52.7) 
−6.4 (−25.1 to 
+9.5) <0.001 
          > 300mg/dl 0.0 (0.0 to 3.4) 0.0 (0.0 to 4.7) 0.0 (−2.1 to +0.6) 0.61 
Data are mean (SD) or median (interquartile range). 
a Closed loop minus control. A positive value indicates the value was higher on the closed loop 
compared with control. 
b Percentage time calculated using conservatively corrected sensor values. 
SUPPLEMENTARY DATA 
 
©2014 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2644/-/DC1 
Supplementary Table 4. Safety evaluation.  
 
 Overnight closed 
loop 
(N = 16 subjects) 
Control  
(N = 16 subjects) 
Number of severe hypoglycaemia  
 
0 0 
Number of subjects experiencing 
severe hypoglycaemia  
0 0 
Number of elevated ketones 
measurementsa 
2 2 
Number of subjects experiencing 
elevated ketones measurements 
2 1 
a Ketones > 1.5mmol/l  
 
Supplementary Table S5. Weekly trends during overnight closed-loop insulin delivery.  
 
 Week 1 
(N = 16 subjects)
Week 2  
(N = 16 subjects) 
Week 3
(N = 16 subjects)
From 23:00 to 07:00    
      Number of evaluable nights 88 90 91 
      Time spent at glucose level 
(%)a:    
         70 to 144mg/dl 64 (42 to 81) 65 (47 to 81) 64 (46 to 77) 
           < 70mg/dl 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.5) 0.1 (0.0 to 0.4) 
           > 144mg/dl 31.0 (17.4 to 55.2) 
27.5 (13.6 to 
49.0) 
30.1 (15.3 to 
50.3) 
      Basal insulin delivery (U) 8.6 (6.7 to 11.1) 7.7 (6.3 to 10.1) 8.4 (6.4 to 10.8) 
      Bolus insulin delivery (U) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 
      Total insulin delivery (U) 9.3 (7.0 to 13.1) 8.1 (6.5 to 11.1) 8.9 (6.8 to 12.8) 
From midnight to midnight (24 hours)    
      Number of evaluable days 87 89 76 
      Time spent at glucose level 
(%)a:    
         70 to 144mg/dl 47 (35 to 61) 51 (40 to 61) 50 (39 to 61) 
           < 70mg/dl 0.3 (0.1 to 1.0) 0.4 (0.1 to 1.6) 0.4 (0.1 to 1.0) 
           > 144mg/dl 47.9 (34.1 to 60.8) 
46.0 (30.6 to 
57.5) 
45.5 (33.8 to 
58.2) 
      Basal insulin delivery (U)  24.3 (18.9 to 32.4) 
23.3 (18.0 to 
29.0) 
21.4 (17.7 to 
29.8) 
      Bolus insulin delivery (U) 23.2 (19.3 to 33.3) 
24.6 (19.7 to 
32.8) 
26.5 (20.7 to 
33.2) 
      Total insulin delivery (U) 49.0 (39.4 to 63.5) 
50.3 (39.6 to 
57.1) 
51.2 (39.9 to 
61.7) 
Data are mean (SD) or median (interquartile range). 
a Percentage time calculated using conservatively corrected sensor values. 
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Supplementary Table 6. Outcomes using native CGM values from 0200 to 0700.  
 
 Overnight 
closed loop 
(N = 16 
subjects) 
Control  
(N = 16 
subjects) 
Paired 
differencea 
 
P 
From 02:00 to 07:00     
      Time spent at glucose level 
(%)b:     
           70 to 144mg/dl 84 (60 to 100) 46 (3 to 89) +30 (−3 to +70) <0.001 
           70 to 180 mg/dl 100 (88 to 100) 81 (29 to 100) +10 (0 to +59) <0.001 
           < 54mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.05 
           < 63mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.04 
           < 70mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.02 
           > 144mg/dl 9.0 (0.0 to 34.2) 40.9 (0.0 to 96.7) 
−18.3 (−70.4 to 
+4.7) <0.001 
           > 180mg/dl 0.0 (0.0 to 4.0) 0.0 (0.0 to 61.1) 0.0 (−54.2 to 0.0) <0.001 
           > 300mg/dl 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.47 
Data are mean (SD) or median (interquartile range). 
a Closed loop minus control. A positive value indicates the value was higher on the closed loop 
compared with control. 
b Percentage time calculated using conservatively corrected sensor values. 
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Supplementary Table 7. List of competencies assessed at the end of training on closed loop 
system.  
 
 Switching *CAD ON/OFF 
 Checking battery level on CAD  
 Awareness of importance of connecting CAD to mains power with lead provided 
overnight 
 Connecting CAD to Companion via USB cable 
 Being aware of keeping the CAD and DANA-R insulin pump as close together as 
possible to ensure connectivity 
 Checking if Companion is connected on CAD screen 
 Starting closed-loop 
 Stopping closed-loop  
 Understanding “Hypo alarms will be switched-off” message  
 Understanding meaning of “Suspended closed-loop” mode and  “Cannot 
continue-reverted to open loop”  
 Understanding how to check alarms audio  
 Understanding the concept of closed-loop delivery  
 Understanding information on DANA-R pump screen during closed-loop delivery   
 Understanding you must deliver a manual bolus with food  
 Understanding the process of delivering a meal bolus during closed-loop 
 Understanding the importance of calibration checks 
 Understanding the importance of alarms being switched ON on the Companion 
during closed-loop 
*CAD stands for control algorithm device (ultraportable OQO laptop) 
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Supplementary Figure 1. Flow of participants through the trial. 
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Supplementary Figure 2. Overnight closed loop during a sample study night. Closed loop 
started at 21:40 and stopped at 07:30. Continuous glucose measurements are shown by light 
red squares, fingerstick calibration check is shown by a dark square (21:10), insulin delivery is 
shown by heavy blue line, and preprogrammed insulin delivery (not administered but shown for 
illustration) by thin blue line. The target range between 3.9 and 8.0mmol/l (70  and 144mg/dl) is 
denoted by dashed red line. 
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Supplementary Figure 3. 24hour profiles of sensor glucose (top panel) and insulin delivery 
(bottom panel) during closed loop and control.  The target glucose range 70 to 144 mg/dl is 
denoted by the dashed lines. Median [interquartile range] is shown.  
 
 
